Nicole Meyerson

Nicole Meyerson supports clients with research and analysis focused on Medicaid, state health policy trends, and the impact of federal health reform.

With experience in state health policy and value-based initiatives, she applies her background to a broad range of client projects.

Prior to joining Avalere, Nicole was a health policy fellow at ML Strategies, researching, analyzing, and authoring briefs to present to clients on Medicaid 1115 waivers. Nicole also represented the firm and clients at Congressional hearings, stakeholder meetings, and at MedPAC and MACPAC public meetings. Nicole holds an MPH in health policy from the George Washington University’s Milken Institute School of Public Health and BA in human development and public health from Oregon State University.

Authored Content

The intersection of upcoming changes to drug pricing metrics will require new methods of calculating and reporting government pricing with implications for net pricing and contracting strategies.

Medicaid will continue to experience considerable changes at the state and federal levels, both in terms of beneficiary demographics and the payer landscape. Stakeholders should consider how upcoming elections, policy proposals, and COVID-19 will impact benefits and payer dynamics.

As control of the Medicaid drug benefit continues to shift from managed care organizations to states, manufacturers should understand unique benefit dynamics in each state, particularly as Medicaid enrollment is likely to increase amid the COVID-19 pandemic.